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previous studies, 91% of bilateral MD patients demonstrate bilateral hypoplasia of the endolymphatic
sac (ES) upon histological and radiological examination of their inner ears. Here, we seek to validate
a radiological marker for ES hypoplasia that predicts the risk for future progression to bilateral MD in
individual patients.Methods: Patients with unilateral MD and radiological evidence for ES hypoplasia
in either the clinically affected inner ear (cohort MDuni-hpuni) or both inner ears (cohort MDuni-hpbi)
were included. Given our hypothesis that ES hypoplasia critically predisposes the inner ear to MD, we
expected progression to bilateral MD only in the MDuni-hpbi cohort. To investigate eventual progression
to bilateral MD, clinical, audiometric, and imaging data were retrospectively collected over follow-up
periods of up to 31 years.Results: A total of 44 patients were included in the MD-hpuni (n = 15) and
MDuni-hpbi (n = 29) cohorts. In line with our radiology-based predictions, none (0/15) of the MD-hpuni
patients exhibited progression to bilateral MD, whereas 20/29 (69%) MD-hpbi patients have already
progressed to bilateral MD. Using the Kaplan–Meier estimator, bilateral disease progression would be
observed in 100% of MD-hpbi patients 31 years after the initial diagnosis with an estimated median time
to bilateral progression of 12 years. The nine MD-hpbi patients who, so far, remained with unilateral
disease demonstrated a median time since initial (unilateral) MD diagnosis of only 6 years and are thus still
expected to progress to bilateral disease.Conclusion: Progression to bilateral MD adheres to predictions
based on the radiological presence or absence of ES hypoplasia. This prognostic tool, if validated by
prospective long-term studies, will provide clinically relevant information about a patient’s future disease
burden and will help to select more personalized treatment regimens.
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Objective:Meniere’s disease (MD) progresses from unilateral to bilateral disease in up to
50% of patients, often chronically and severely impairing balance and hearing functions.
According to previous studies, 91% of bilateral MD patients demonstrate bilateral
hypoplasia of the endolymphatic sac (ES) upon histological and radiological examination
of their inner ears. Here, we seek to validate a radiological marker for ES hypoplasia that
predicts the risk for future progression to bilateral MD in individual patients.
Methods: Patients with unilateral MD and radiological evidence for ES hypoplasia in
either the clinically affected inner ear (cohort MDuni-hpuni) or both inner ears (cohort
MDuni-hpbi) were included. Given our hypothesis that ES hypoplasia critically predisposes
the inner ear to MD, we expected progression to bilateral MD only in the MDuni-hpbi
cohort. To investigate eventual progression to bilateral MD, clinical, audiometric, and
imaging data were retrospectively collected over follow-up periods of up to 31 years.
Results: A total of 44 patients were included in the MD-hpuni (n = 15) and MDuni-hpbi (n
= 29) cohorts. In line with our radiology-based predictions, none (0/15) of the MD-hpuni
patients exhibited progression to bilateral MD, whereas 20/29 (69%) MD-hpbi patients
have already progressed to bilateral MD. Using the Kaplan–Meier estimator, bilateral
disease progression would be observed in 100% of MD-hpbi patients 31 years after
the initial diagnosis with an estimated median time to bilateral progression of 12 years.
The nine MD-hpbi patients who, so far, remained with unilateral disease demonstrated
a median time since initial (unilateral) MD diagnosis of only 6 years and are thus still
expected to progress to bilateral disease.
Conclusion: Progression to bilateral MD adheres to predictions based on the
radiological presence or absence of ES hypoplasia. This prognostic tool, if validated by
prospective long-term studies, will provide clinically relevant information about a patient’s
future disease burden and will help to select more personalized treatment regimens.
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INTRODUCTION
Meniere’s disease (MD), a chronic inner ear disorder, causes
fluctuating vestibular and auditory symptoms and exhibits a
highly variable disease course among patients (1, 2). Most
severely affected are the 10–50% of patients (3–5) in whom the
disease progresses to bilateral MD, often years to decades after its
initial (unilateral) manifestation. Due to bilateral vestibulopathy,
patients with bilateral MD experience chronic debilitating
vestibular symptoms, such as oscillopsia and imbalance, and
a broad range of cognitive and emotional impairment (6).
Moreover, bilateral MD often leads to severe to profound hearing
loss with unserviceable speech discrimination (7, 8). A biomarker
for future bilateral disease would allow clinicians to identify
those patients, to preemptively counsel them about the expected
disease course, and to personalize therapy regimens in clinically
meaningful ways.
In this study, radiological evidence for endolymphatic sac
(ES) hypoplasia (9, 10), i.e., the suspected etiopathology in
approximately 30% ofMD patients, with the designated endotype
“MD-hp” (11), was used to prognosticate disease laterality. In
a recent human temporal bone study, either of two pathologies
of the ES, i.e., degeneration or developmental hypoplasia, was
consistently found in cases with clinical MD (9). These ES
pathologies (“endotypes”) can be linked to the pathogenesis of
endolymphatic hydrops, a histopathologic and radiologic marker
of MD (9, 12). The subtype of ES pathology correlates with the
course of the vestibular aqueduct, which–in contrast to the ES
epithelium–can be visualized in clinical imaging (10). In MD,
the course of the vestibular aqueduct can therefore be used
as a radiologic surrogate marker for the underlying subtype of
cellular ES pathology (10). Using this marker, it has been shown
in clinical patients that the pathologic endotypes are associated
with differing clinical phenotypes (11). In MD-hp patients, one
or both inner ears may exhibit ES hypoplasia. However, to date,
it is not clear whether ES hypoplasia critically predisposes to
MD. Here, we hypothesized that progression to bilateral MD
only occurs in patients with bilateral ES hypoplasia (cohort




This study was approved by the local ethics committee (KEK-ZH-
Nr. 2016-01619/2019-01006) in accordance with the Declaration
of Helsinki and its amendments. Informed consent has been
obtained from all participants.
Abbreviations: ATVA, angular trajectory of the vestibular aqueduct; cVEMP,
cervical vestibular-evoked myogenic potential; ES, endolymphatic sac; Gd-MRI,
gadolinium-enhanced MRI; HRCT, high-resolution CT; MD, Meniere’s disease;
MD-dg, Meniere’s disease associated with a degeneration of the endolymphatic sac
(and a normal vestibular aqueduct); MD-hp, Meniere’s disease associated with a
developmental hypoplasia of the vestibular aqueduct and endolymphatic sac.
Study Design and Participants
Patients from an interdisciplinary tertiary neurotology center
fulfilling the following inclusion criteria were included into the
study between August 2019 and December 2020: (i) patients
with an initial diagnosis of unilateral definite MD (1, 13),
(ii) radiological evidence for uni- or bilateral ES hypoplasia
(endotype MD-hp), (iii) endolymphatic hydrops in the affected
ear (see next paragraph), and (iv) age ≥18 years. The time
point of first MD manifestation was defined by the first reported
episode of spontaneous vertigo lasting >20min or by the
first audiometrically documented hearing loss, which matched
the MD diagnostic criteria (1, 13). Patients with secondary
Meniere’s syndrome due to a known pathology were excluded
(14, 15). Bilateral progression was defined as recurrence of vertigo
attack(s) and audiometrically documented hearing loss in the
second ear (16).
Temporal Bone Imaging
At the time of initial clinical work-up, 3 Tesla gadolinium-
enhanced MRI (Gd-MRI) of the temporal bones was performed
using a 32-channel phased array coil to visualize endolymphatic
hydrops (17, 18) and to exclude other intra- or retrolabyrinthine
pathology. Endolymphatic hydrops grading was performed
separately for the cochlea and the vestibule (18) by an
experienced neuroradiologist (BS). In some patients, additional
high-resolution CT (HRCT) of the temporal bones was
performed, e.g., to exclude a dehiscence syndrome.
Vestibular Aqueduct Measurements and
Patient Endotyping
The angular trajectory of the vestibular aqueduct (ATVA) was
determined for each inner ear in HRCT data if available or in
Gd-MR imaging data (3D real inversion recovery sequence). An
ATVA with an angle αexit >140
◦ indicated ES hypoplasia, and
an αexit <120
◦ indicated a normal ES (Figure 1), as defined
previously (9, 10). Patients with αexit >140
◦ and <120◦ on
the clinically affected and the non-affected side, respectively,
were assigned to the MDuni-hpuni cohort, whereas those with
an αexit >140
◦ on both sides were assigned to the MDuni-
hpbi cohort.
Statistical Analysis
Values are reported as absolute numbers (percentage) or means
with standard deviation (SD) and range. Continuous variables
were analyzed using a two-tailed Student’s t-test for independent
samples. For binary variables, a Fisher’s exact test was performed.
A p < 0.05 was considered as statistically significant. The
Kaplan–Meier method was used to quantify the percentage
of patients with progression to bilateral MD. The Log-rank
(Mantel–Cox) test was used to compare Kaplan–Meier curves.
Follow-up times were censored for all cases at the time when
the final analysis was initiated (January 2021). Statistical analyses
were performed using Prism for Apple Macintosh, version 7.0
(GraphPad Software, Inc., La Jolla, CA, USA).
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RESULTS
Clinical Features of the Study Cohorts
A total of 44 patients were included between August 2019
and January 2020. From those, 15 patients were assigned to
the MD-hpuni cohort, and 29 patients to the MD-hpbi cohort
based on the radiological criteria defined above (Table 1).
In 35/44 (80%) patients, HRCT was available and used for
vestibular aqueduct measurements. In the remaining 9/44
(20%) patients, Gd-MRI was used for vestibular aqueduct
measurements. Male to female ratio, mean age at MD onset
FIGURE 1 | Illustration of normal and hypoplastic ES morphology in temporal
bone HRCT from an MDuni-hpuni patient. Axial plane CT images show a
normal, bent course of the 2D-reconstructed vestibular aqueduct on the right
(magenta outlines in (a); ATVA with αexit = 72
◦), indicating the presence of a
normal ES. The panel below shows a drawing of a normal ES located within a
normal vestibular aqueduct (a′). On the left side, an abnormal, straight course
of the vestibular aqueduct was found (magenta outlines in (b); ATVA with αexit
= 144◦), indicating a hypoplastic ES. The panel below shows a drawing of a
hypoplastic ES located within a hypoplastic vestibular aqueduct (b′). This
patient had a 9-year history of left-sided MD. Insets show the geometric
measurement results for the ATVA, according to previously described methods
(10). Co, cochlea; ES, endolymphatic sac; IAC, internal auditory canal; VA,
vestibular aqueduct; Ve, vestibule. Scale bar: 5mm. (a′,b′) are adapted from
Eckhard et al. (9), under the terms of the Creative Commons CC BY license
(http://creativecommons.org/licenses/by/4.0/).
(time point of initial diagnosis), and range of disease duration
did not significantly differ between both cohorts (Table 1).
Among the 44 MD-hp patients, 14 (32%) had a positive family
history for MD, 3 (7%) had migraine, and none had a known
autoimmune disorder.
Progression to Bilateral MD Is Exclusively
Observed in the MD-hpbi Cohort
Within 30 and 31 years from onset of MD, none (0/15) of the
MD-hpuni patients and 20/29 (69%)MD-hpbi patients progressed
to bilateral MD, respectively (p = 0.001; Figure 2, Table 1).
In MD-hpbi patients, the estimated median time to bilateral
progression was 12 years. The proportion of patients with
bilateral MD was estimated to increase to 43% after 10 years
and to 90% after 30 years with unilateral MD, respectively
(Figure 2).
FIGURE 2 | Kaplan–Meier plot for progression to bilateral MD in the MD-hpuni
and MD-hpbi cohorts. Ticks indicate censored cases. In the MD-hpbi cohort,
median time to bilateral progression was 12 years. None of the MD-hpuni
patients developed bilateral disease within 30 years. Dashed lines indicate
95% confidence intervals.
TABLE 1 | Demographics and clinical characteristics of the MD-hp cohorts.
MD-hp (n = 44) MD-hpuni (n = 15) MD-hpbi (n = 29) MD-hpuni vs. MD-hpbi
Male to female ratio, no. (%) 37:7 13 (87%):2 (13%) 24 (83%):5 (17%) p = 0.99
Mean age at onset, years (SD) 39.0 (11.6) 39.1 (7.8) 39.0 (13.2) p = 0.96
Mean disease duration, years (SD, range) 14.7 (12.1) 10.7 (7.7, 2–30) 16.8 (13.7, 1–31) p = 0.12
Unilateral to bilateral MD ratio, no. (%) 24 (55%):20 (45%) 15 (100%):0 (0%) 9 (31%):20 (69%) p < 0.0001
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Prospective Observation of Bilateral
Disease Progression in an MDuni-hpbi
Patient
This male patient, who was followed up in our neurotology
center between age 53 and 58, was prognosticated to develop
bilateral MD based on temporal bone HRCT imaging signs
for bilateral ES hypoplasia (Figures 3a,b). The patient initially
was seen at age 53 with complaints of monthly, spontaneous
vertigo episodes (up to 6 h), accompanied by hearing loss and
fullness in his right ear. Pure tone audiometry at the time showed
moderate sensorineural hearing loss at low and high frequencies
(“peak pattern”) on the right side (Figures 3c,d). Inner ear
Gd-MRI demonstrated grade 1 cochleovestibular hydrops in
the right ear (Figures 3e,f), supporting the clinical diagnosis
of right definite MD. The patient was started on betahistine
(48mg twice daily). Over the following 5 years, in which he
was followed up at 6–12-month intervals, he reported only
one more vertigo attack. During this time, right-sided hearing
progressively deteriorated to a moderate sensorineural hearing
loss that affected all frequencies [Figure 3c, age 53–58 (I)]. A
left-sided age-appropriate high-frequency sensorineural hearing
loss was observed during that time [Figure 3d, age 54–58 (I)].
At age 58, the patient again experienced weekly, hours-long
spontaneous vertigo episodes as well as a new hearing loss
in his previously unaffected left ear. Pure tone audiometry at
that time demonstrated a new low-frequency hearing loss in
the left ear (Figure 3d), and sequential Gd-MRI of the inner
ears showed a new cochlear hydrops grade 1 in the left ear
(Figures 3g,h). The clinical diagnosis was revised accordingly
to bilateral definite MD. Of note, a further progression of
high-, but not low-frequency sensorineural hearing loss was
observed for the right ear supporting the notion of an anticipated
age-related decline in the right ear, whereas vertigo attacks
now originated from the left ear [Figures 3c,d, age 58 (I) and
58 (II)].
DISCUSSION
MD-hp patients statistically have a 25% risk for developing
bilateral disease, which is 5-fold higher than other MD patients
(11). Thus, providing MD-hp patients with a personalized
prognosis, instead of a mere statistical one-in-four chance
for bilateral disease progression, would advance the clinical
management of this patient group, which is at highest risk for
a severe disease course, in a clinically relevant manner.
MD-hp patients are distinguished by a developmentally
rudimentary, i.e., hypoplastic, ES (Figure 1b′), which has
been initially described in sporadic MD cases (19–22) and
was more recently demonstrated as a consistent finding in
about 30% of pathology cases with a clinical MD diagnosis
(9)—now designated as the MD-hp patient group (11).
Pathophysiologically, the absence of normal ion transport
mechanisms in the hypoplastic ES epithelium is believed to
be the key pathology that causes disturbances of the inner
ear fluids and, ultimately, endolymphatic hydrops and clinical
symptoms (9, 23). ES hypoplasia is consistently associated with
FIGURE 3 | Exemplary clinical case progressing to bilateral disease. (a,b) In
this patient, ATVA measurements on temporal bone HRCT images performed
at age 53 determined angles (αexit ) consistent with bilateral ES hypoplasia
(2D-reconstructed course of the vestibular aqueduct outlined in magenta).
Scale bar: 5mm. (c,d) Audiogram data (air conduction thresholds) before MD
first manifested (age 47), after onset of unilateral (right) MD [ages 53–58 (I)],
and shortly after progression to bilateral disease [age 58 (II)]. (e,f) Gd-MRI at
the time point of initial MD diagnosis (age 53) demonstrated grade 1 (18)
cochleovestibular hydrops (black arrowheads) in the right inner ear. (g,h)
Sequential Gd-MRI, after clinical and audiometric data indicated progression
to bilateral MD (age 58), demonstrated grade 1 cochleovestibular hydrops in
the right and left inner ears. Scale bar: 5mm.
a hypoplastic bony VA, which can be radiologically visualized
and was established as a clinical surrogate marker (ATVA) for the
presence of ES hypoplasia (10).
This present preliminary and previous (11) data suggest that
the radiological ATVA marker has absolute positive and negative
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predictive power for making this personalized prognosis. If
ultimately validated by long-term prospective studies, this would
allow clinicians (i) to counsel patients about aspects of their
future disease course, in particular about the long-term impacts
on hearing and balance functions; (ii) to make better decisions
on whether ablative therapies, such as intratympanic gentamicin
or vestibular neurectomy, can be considered; and potentially also
(iii) to screen family members and children fromMD-hp patients
for their risk of developing uni- or bilateral MD. Furthermore,
the ATVA marker enables to define clinically more homogenous
subgroups of MD patients for future (genomic) studies.
In bilateral MD, non-ablative treatments, such as
intratympanic steroids, should be preferred over ablative
treatments, which should be avoided (16). Using the ATVA
marker, progression to bilaterality can be anticipated in MD-hpbi
patients and virtually excluded in MD-hpuni patients. Therefore,
this clinical tool may allow to obviate iatrogenic bilateral
vestibular loss and/or hearing loss due to ablative treatments
in MD-hpbi patients. On the other hand, in MD-hpuni patients
with an infinitesimal risk for bilateral progression, ablative
treatments, such as intratympanic gentamicin administration,
may be liberally used.
ES surgery is commonly considered as a non-ablative
treatment of MD (16). It should be noted, however, that in MD-
hp patients, the ES is hypoplastic and anteriorly displaced. These
anatomical abnormalities impede the surgical approach of the
ES via the commonly used transmastoid route; furthermore, the
hypoplastic ES occasionally does not exit the temporal bone at all.
Of note, the surgical non-visualization rate of the ES during ES
surgery corresponds to the percentage of MD-hp patients among
all MD patients (11, 24). Although there is lacking evidence for
a beneficial effect of ES surgery (25), this “non-ablative” surgical
treatment–if considered–may therefore be particularly avoided in
MD-hp patients.
Notably, among other proposed markers for predicting
bilateral MD (2, 18), cervical vestibular-evoked myogenic
potential (cVEMP) metrics were retrospectively found to be
altered, with high specificity and sensitivity, in clinically yet
unaffected contralateral ears 24–288 months before clinical
symptoms manifested (26, 27). The actual time course of
these cVEMP changes and their earliest appearance during the
presymptomatic phase remain to be investigated. The present
radiological (ATVA)markermay potentially identify inner ears at
risk even before anyMD-associated functional changes occur, i.e.,
in early childhood, when the temporal bone anatomy is matured.
However, its validity for predicting MD in asymptomatic
individuals with ES hypoplasia needs to be investigated.
Regarding the potential clinical use of the ATVA marker,
the following points should further be considered: (i) the time
interval from initial MD diagnosis to bilateral affection is highly
variable among patients (4, 5, 11, 28, 29) and cannot be predicted
with the ATVAmarker; (ii) the measurement of an αexit of<120
◦
in the contralateral ear does not with absolute certainty exclude
progression to bilateral disease, since a different MD-causing
process can affect this ear (i.e., another MD endotype) (9, 11),
although this remains hypothetical; and (iii) the determination
of the ATVA on both sides in Gd-MRI (3D IR sequence) data
requires systemic (i.v.) delivery of the Gd-contrast agent.
In conclusion, ongoing observations will determine whether
the promising preliminary data hold up and whether both study
cohorts remain “true to prediction,” thus ultimately validating
the ATVA marker as a prognostic tool for bilateral disease
progression in MD-hp patients.
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